~~<i id='2634D7ADA4'><strike id='2634D7ADA4'><tt id='2634D7ADA4'><pre id='2634D7ADA4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

focus

author：explore 2025-09-27 22:49:41 - browse：41145

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Generate Biomedicines machine learning biotech raises $273M

knowledge

entertainment

explore

entertainment

leisure time

AdobeThistimelastyear,membersofCongresswereworkingaroundtheclocktodraftandpasstheInflationReductionA

WSS

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Resistance to opioid

Why don't Americans have at

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

STAT Boddities: What happens to the brain when we get scared?

New Covid vaccine is recommended for everyone 6 months or older

explore

focus

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Ebola vaccine can save some who are already sick, per new study

Affirmative action in medical school literally saved lives

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Virginia high school admissions case could be legal follow

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Continuity nursing helped my family in our darkest PICU moments

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Anesthesiologist group: stop taking Ozempic before surgery

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

entertainment

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Congress might make insulin pumps more accessible to the blind

Report cites 'urgent' need to recruit more diverse clinical trial participants

Congress might make insulin pumps more accessible to the blind

What to make of Biden’s latest efforts on cancer research

Congress considering partial increase for doctor pay in Medicare

entertainment

explore

entertainment

leisure time